As the largest resource of information specific to women's brain health, we are sure you will find what you are looking for, and promise that you will discover new information.
Published on: July 23, 2014
by Diagnostic Imaging:
Positron emission tomography (PET) with [18 F]flutemetamol resulted in changes in the diagnostic process work-up of patients with early onset dementia, according to a study presented at the Alzheimer’s Association International Conference 2014 (AAIC).
Researchers from the Netherlands and the United States undertook a study to examine the diagnostic value of [18F]flutemetamol PET in assessing patients with early onset dementia. “Early and accurate diagnoses may have implications for both prognosis and treatment among patients with early onset dementia,” lead investigator Marissa Zwan, MD, said in a release. “Greater diagnostic confidence supports better patient management and helps physicians to determine appropriate treatment options, as well as helping patients and caregivers to plan for the future.”
Eighty patients with early onset dementia (before age 70) participated in the study and underwent an [18F]flutemetamol PET scan, which was visually assessed as amyloid positive or negative. Physician confidence in the diagnosis based on routine diagnostic work-up for dementia was 90 percent.
The results showed that 48 of 63 patients (76 percent) who had been diagnosed with Alzheimer’s disease (AD) prior to the imaging were [18 F]flutemetamol positive. Four out of 17 patients (24 percent) diagnosed with other dementias were also [18 F]flutemetamol positive.
“Access to PET results led to a change in diagnosis in 16 (20 percent) patients,” the authors noted. “In 11 out of 13 patients, a negative PET scan caused a change of the initial AD diagnosis to another dementia. In three out of four other dementia patients, the initial diagnosis was changed to AD after receiving a positive PET scan.”
Twenty-seven patients (34 percent), who had an initial clinical diagnosis of Alzheimer’s disease had a change in their healthcare management following the PET results. Thirteen patients underwent additional ancillary investigations after access to the PET scan results.
The authors concluded that PET resulted in changes in clinical diagnosis of some patients with early-onset dementia and, in turn, in their management.
Thirty-six million people worldwide suffer from Alzheimer’s disease and dementia. In Canada, 25,000 new cases are diagnosed each year. Those sobering numbers have researchers around the globe racing to come up with new ways to...
he Food and Drug Administration issued new guides on drug development for neurological disorders. This sets the stage for possible treatments for Alzheimer’s. The disease-oriented development guide documents will provide details on how researchers...
For young adults with autosomal dominant Alzheimer’s disease (AD), molecular markers can identify changes associated with the disease before clinical onset, according to a study published online Feb. 12 in JAMA Neurology. Yakeel T. Quiroz, Ph.D., from Massachusetts...
The material presented through the Think Tank feature on this website is in no way intended to replace professional medical care or attention by a qualified practitioner. WBHI strongly advises all questioners and viewers using this feature with health problems to consult a qualified physician, especially before starting any treatment. The materials provided on this website cannot and should not be used as a basis for diagnosis or choice of treatment. The materials are not exhaustive and cannot always respect all the most recent research in all areas of medicine.